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Abstract 
Background: Extracorporeal membrane oxygenation (ECMO) has been increasingly studied as a life support modal-
ity, but it is unclear if its use has changed over time. Recent publication shows no significant trend in use of ECMO 
over time; however, this report does not include more recent data. We performed trend analysis to determine if and 
when the use of ECMO changed in the past decade.
Results: We identified hospitalizations (2000–2011) in the Nationwide Inpatient Sample during which ECMO was 
recorded. We used a segmented linear regression model to determine trend and to identify a temporal change point 
when rate of ECMO use increased. ECMO use gradually grew until 2007, at which time there was a dramatic increase 
in the rate (p = 0.0003). There was no difference in mortality after 2007 (p = 0.3374), but there was longer length of 
stay (p = 0.0001) and smaller percentage of women (p = 0.005).
Conclusions: There has been a marked increase in ECMO use since 2007. As ECMO use becomes more common, 
further study regarding indications, cost-effectiveness, and outcomes is warranted to guide optimal use.
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Findings
Background
Extracorporeal membrane oxygenation (ECMO) pro-
vides temporary means of support for cardiopulmonary 
failure when conventional methods fail. First used in 
adults during the 1970s, a renewed interest has occurred 
due technological advances, increased safety, and 
decreased complications [1]. In addition, renewed inter-
est in ECMO by intensivists has also been due to a large 
randomized controlled trial suggesting efficacy of ECMO 
in respiratory failure, reports of successful use in respira-
tory failure cases during the H1N1 influenza pandemic, 
and in more recent reports as a bridge to lung transplan-
tation [2–5].
A recent study has suggested that the trend in ECMO 
admissions is not significantly increasing, although 
these data are reported only up to 2009 [6]. However, 
it does appear that hospital charges and length of stay 
are increasing, perhaps associated with a shift in use of 
ECMO to patients with worse outcomes [6]. Thus, the 
objective of this study was to determine how the national 
frequency of ECMO use has changed over the past dec-
ade in the United States (US) with a larger number of 
years of data than previously reported, and to deter-
mine the point in time point at which the use may have 
changed. We also describe the demographics, length of 
stay, and mortality of patients receiving ECMO during 
hospitalization. Understanding trends will help hospitals 
plan for increases in use and help inform future research 
studies regarding safety, efficacy, and appropriate indica-
tions of use.
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Methods
All data were extracted from the Nationwide Inpatient 
Sample, the largest all-payer database of national dis-
charges in the US [7]. The database is maintained as part 
of the Healthcare Cost and Utilization Project by the 
Agency for Healthcare Research and Quality, and con-
tains data from a 20  % stratified sample of nonfederal 
acute care hospitals. The Agency for Healthcare Research 
and Quality allows access to the data with a signed data-
use agreement. To adjust for yearly changes in the sam-
pling design, we applied weights provided by the Agency 
for Healthcare Research and Quality. All analyses were 
performed using R, version 2.15.1 (R Foundation for 
Statistical Computing). Our institutional review board 
determined that this project was not human subjects 
research.
We identified all hospitalizations in adults 18 years of 
age and older from January 2000 through December 2011 
during which either a primary or secondary procedure of 
ECMO was recorded. For case ascertainment, we used 
the International Classification of Diseases, 9th revision, 
Clinical Modification (ICD-9-CM) code 39.65. We first 
aggregated all cases by month to produce a national sam-
ple of cases of ECMO over time. Cases were assigned to 
calendar month based on the date that the patient was 
admitted to the hospital. To comply with publication 
guidelines regarding low counts, prior to our analysis, we 
aggregated monthly counts to a 6 month period.
Statistical analysis
The purpose of this analysis was to determine whether 
use of ECMO has increased during the study period and 
to determine if the rate of use has changed at any point 
during the study period. We used a segmented linear 
regression model to answer both questions. The model 
can be written as:
where y is the dependent outcome variable (ECMO inci-
dence), t is the time period (6 month interval), t0 is the 
change point, Icp is an indicator variable for the change 
point, and ε ∼ N (0, σ 2). The indicator Icp assumes a value 
of 1 for time periods t at or beyond the change point t0, 
and assumes a value of 0 otherwise.
We used a data driven approach to investigate the exist-
ence and location of the change point. We visually identi-
fied a specific time period as the most plausible change 
point. We then fit a segmented linear regression model 
based on the selected change point. Residual diagnostics 
were conducted after de-trending the ECMO series to 
investigate whether there was any autocorrelation pattern 
in the residuals. We examined the autocorrelation func-
tion and the partial autocorrelation function for temporal 
y = β0 + β1t + β2
[
(t − t0) ∗ Icp
]
+ ε,
correlation in the residuals, as failure to account for such 
correlation may lead to incorrect inferential conclusions.
Although the change point is visually evident in the 
time series plot, we wished to empirically validate the 
location of this point. We determined a time window 
to capture any potential change point. We then built a 
separate segmented linear regression model for each 
candidate change point within this window. The optimal 
change point was subsequently determined based on the 
model yielding the smallest value of Akaike information 
criterion, with optimal models corresponding to smaller 
values.
To determine shifts in demographics and characteris-
tics, the sample was divided into two groups based on the 
identified change point. For binary outcomes (gender and 
mortality), comparisons of proportions were conducted 
using the Pearson Chi square test. For continuous out-
comes (length of stay and age), comparisons of means 
were conducted using the Wilcoxon rank sum test.
Results
Figure  1 shows a plot of overall ECMO incidence from 
2000–2011. Based on a visual inspection of the plot, we 
chose the first half of 2007 to be the initial change point 
for the investigation of the autocorrelation pattern in the 
residuals. Upon inspection of the autocorrelation func-
tion and partial autocorrelation function, we found no 
evidence of temporal correlation, implying that a seg-
mented linear regression model based on independ-
ent errors is sufficient to model the incidence of ECMO 
use. To confirm the time of our selected change point, 
Fig. 1 Semiannual incidence rates of hospitalizations of patients 
receiving extracorporeal membrane oxygenation in the United States 
2000–2011 (Nationwide Inpatient Sample). The form of the fitted 
model is illustrated by the dashed line segments
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we determined the time window for the coverage of the 
change point to be between 2005 and 2008. Based on 
Akaike information criterion values, the change point 
was confirmed to be the first half of 2007.
Our final segmented linear regression model, based on 
the confirmed change point, shows a significant change 
of slope after the first half of 2007. The form of the fit-
ted model is illustrated in Fig. 1. The slope coefficient for 
the period before the change point (2007) is positive, but 
not statistically significant (p = 0.2595). However, a sig-
nificant change of slope is detected after the change point 
(p = 0.0003). The large escalation in slope indicates that 
there is a significant effect resulting from increased use of 
ECMO after 2007.
Finally, we compared the demographics and character-
istics. We found that for the two groups separated by the 
change point, there are no statistically significant differ-
ences in the mortality rate (66.2 % before 2007 vs. 63.7 % 
after 2007, p = 0.34) and mean age (50.5 vs. 50.4 years, 
p  =  0.88). A higher percentage of males were treated 
with ECMO after the change point (56.9  % before 2007 
vs. 64.3  % after 2007, p  =  0.0050). Patients also had a 
longer mean length of stay after the change point (19.9 
vs. 22.6 days, p < 0.0001).
Discussion
Our results show that national use of ECMO in adults 
was stable until the first half of 2007 when there was a 
marked increase in frequency of use. Comparing patients 
who received ECMO prior to 2007 with those after 2007, 
we found that age and mortality were unchanged. How-
ever, length of stay has increased since 2007 and the fre-
quency of use in males has also increased. These results 
indicate that there has been increasing resources invested 
by institutions in the implementation and use of ECMO 
in hospitalized patients across the nation.
Since the greatest growth in use occurred after 2007, 
the additional years of data in this study allows a more 
complete analysis of the trend over time, explaining the 
difference in results from prior study [6]. The reason for 
this growth in use after 2007 is likely multifold, and may 
include technical advances, improving safety of anticoag-
ulation, as well as more aggressive interventional care in 
acute coronary syndrome and/or concurrent growth and 
acceptance of cardiovascular bridge technologies [1, 4, 8].
Despite advances in technology and increasing expe-
rience, the overall in-hospital mortality rate for patients 
receiving ECMO has remained relatively stable since 
2000 at over 60  %. Because ECMO is primarily admin-
istered to critically ill patients, this high mortality rate 
may reflect the severity of underlying disease rather 
than the treatment itself. The mortality rate we observe 
is likely driven by cardiovascular disease and periopera-
tive rescue. Patients with non-cardiovascular indications, 
including respiratory failure, may have a lower mortality 
rate, and may reflect a willingness to perform this treat-
ment on younger, otherwise healthy patients, requiring 
short term life support for an acute event [6]. Registry 
data and other more granular data sources are important 
to further study mortality by indication.
A major limitation of our study is that we use adminis-
trative data. These results are based on analysis of ICD-
9-CM codes only. Due to this, we are unable to assess 
differences in types of ECMO (e.g. veno-venous vs veno-
arterial) or the individual characteristics of the patient 
in which it was implemented. Similarly, because the 
ICD-9-CM primary diagnostic admission codes varied 
greatly, we were unable to make meaningful conclusions 
regarding the underlying reason for ECMO use and how 
it may be changing over time. Despite these limitations, 
ECMO is an expensive procedure with one ICD-9-CM 
code; it likely that we are correctly identifying cases of 
ECMO use. Most importantly, and for the objective of 
this study, because ECMO use is uncommon, our large 
sample size allows us to estimate overall trends across 
the nation much more reliably than studies based in sin-
gle centers. Our results provide a relatively unbiased view 
of the nation’s use of this resource through hospitaliza-
tion records, complementing current registry data. With 
these data, we are able to explore the use of ECMO dur-
ing hospitalizations on a population level across the US
In conclusion, the use of ECMO has dramatically 
increased in the US since 2007. Because large clinical 
trials will be difficult, it is important to explore indica-
tions and outcomes using observational data. As use of 
ECMO spreads to more centers throughout the United 
States, further research regarding medical and surgical 
care strategies, referral protocols, cost effectiveness, and 




ECMO: extracorporeal membrane oxygenation; ICD-9-CM: International Clas-
sification of Diseases, 9th revision, Clinical Modification; US: United States.
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